TScan Therapeutics Inc. (TCRX)
2.69
0.06 (2.28%)
At close: Jan 15, 2025, 2:37 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | 21.05M | 13.54M | 10.14M | 1.08M | n/a |
| Cost of Revenue | 88.15M | 5.14M | 3.33M | 20.58M | 519.00K |
| Gross Profit | -67.10M | 8.40M | 6.81M | -19.49M | -519.00K |
| Operating Income | -93.46M | -66.64M | -48.64M | -26.23M | -14.21M |
| Interest Income | 8.00M | 1.59M | 16.00K | 106.00K | 552.00K |
| Pretax Income | -89.22M | -66.22M | -48.63M | -26.13M | -13.66M |
| Net Income | -89.22M | -65.81M | -48.63M | -26.02M | -13.11M |
| Selling & General & Admin | 26.35M | 20.35M | 13.83M | 6.74M | 4.77M |
| Research & Development | 88.15M | 59.82M | 44.95M | 20.58M | 9.44M |
| Other Expenses | n/a | 1.59M | 16.00K | n/a | n/a |
| Operating Expenses | 114.51M | 80.17M | 58.78M | 27.32M | 14.21M |
| Interest Expense | 3.76M | 1.18M | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 114.51M | 80.17M | 58.78M | 27.32M | 14.21M |
| Income Tax | n/a | -415.00K | 3.09M | -106.00K | -552.00K |
| Shares Outstanding (Basic) | 65.60M | 24.05M | 23.91M | 24.94M | 24.94M |
| Shares Outstanding (Diluted) | 65.60M | 24.05M | 23.91M | 24.94M | 24.94M |
| EPS (Basic) | -1.36 | -2.74 | -2.03 | -1.04 | -0.53 |
| EPS (Diluted) | -1.36 | -2.74 | -2.03 | -1.04 | -0.53 |
| EBITDA | -80.10M | -59.91M | -45.30M | -25.00M | -13.69M |
| Depreciation & Amortization | 5.36M | 5.14M | 3.33M | 1.23M | 519.00K |